Skip to main content
Top
Published in: Inflammation 2/2009

01-04-2009

Effects of Trefoil Peptide 3 on Expression of TNF-α, TLR4, and NF-κB in Trinitrobenzene Sulphonic Acid Induced Colitis Mice

Authors: Xu Teng, Ling-Fen Xu, Ping Zhou, Hong-Wei Sun, Mei Sun

Published in: Inflammation | Issue 2/2009

Login to get access

Abstract

The trefoil factor (TFF) peptides are major secretory products of mucus cells of the gastrointestinal tract. There were evidences that administration of recombinant human TFF3 is effective in treatment of models of colitis, but the mechanism of the effects of rTFF3 is not fully understood. The main aims of this study is to evaluate effects of intraperitoneal injection recombinant human TFF3 on the expression of tumour necrosis factor α (TNF-α), toll-like receptor 4(TLR4), and nuclear factor κB (NF-κB) in trinitrobenzene sulphonic acid (TNBS) induced colitis mice. Distal colitis was induced in BALB/C mice by intracolonic administration of TNBS in ethanol. Treated with administration rhTFF3 for treatment group(5 mg/ml; approximately 0.5 mg/mouse), and normal saline for control for 5 consecutive days. Colonic damage score, tissue myeloperoxidase (MPO) activity, TLR4, NF-κB mRNA expression, and tissue TNF-α, TLR4, NF-κB production were determined, respectively. Once daily application of hTFF3 for 5 days after TNBS/ethanol had been injected, both microscopic and macroscopic injury and inflammatory index had been reduced compared with controls. In addition, decreased tissue TNF-α, TLR4, NF-κB production, and TLR4, NF-κB mRNA expression had been found. This study has shown that hTFF3 may have therapeutic potential in the treatment of inflammatory bowel disease, and one of the mechanisms may related to inhibit the TLR4/NF-κB signaling pathways.
Literature
1.
go back to reference Salzman, N. H., and C. L. Bevins. 2008. Negative interactions with the microbiota: IBD. Adv. Exp. Med. Biol. 635:67–78.PubMedCrossRef Salzman, N. H., and C. L. Bevins. 2008. Negative interactions with the microbiota: IBD. Adv. Exp. Med. Biol. 635:67–78.PubMedCrossRef
2.
go back to reference Sheikh, S., J. Uno, K. Matsuoka, and S. Plevy. 2008. Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. Clin. Immunol. 127(3):270–279 Jun.PubMedCrossRef Sheikh, S., J. Uno, K. Matsuoka, and S. Plevy. 2008. Abnormal mucosal immune response to altered bacterial flora following restorative proctocolectomy in patients with ulcerative colitis: serologic measures, immunogenetics, and clinical correlations. Clin. Immunol. 127(3):270–279 Jun.PubMedCrossRef
3.
go back to reference Yan, Y., G. Dalmasso, H. T. Nguyen, T. S. Obertone, L. Charrier-Hisamuddin, S. V. Sitaraman, et al. 2008. Nuclear factor-kappaB is a critical mediator of Ste20-like proline-/alanine-rich kinase regulation in intestinal inflammation. Am. J. Pathol. 173(4):1013–1028 Oct.PubMedCrossRef Yan, Y., G. Dalmasso, H. T. Nguyen, T. S. Obertone, L. Charrier-Hisamuddin, S. V. Sitaraman, et al. 2008. Nuclear factor-kappaB is a critical mediator of Ste20-like proline-/alanine-rich kinase regulation in intestinal inflammation. Am. J. Pathol. 173(4):1013–1028 Oct.PubMedCrossRef
9.
go back to reference Fuss, I. J., M. Neurath, M. Boirivant, J. S. Klein, C. de la Motte, S. A. Strong, et al. 1996. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261–1270.PubMed Fuss, I. J., M. Neurath, M. Boirivant, J. S. Klein, C. de la Motte, S. A. Strong, et al. 1996. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261–1270.PubMed
13.
go back to reference Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immun. 2:675–680. doi:10.1038/90609.CrossRef Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immun. 2:675–680. doi:10.​1038/​90609.CrossRef
19.
go back to reference Sandborn, W. J., and S. B. Hanauer. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5(2):119–133.PubMed Sandborn, W. J., and S. B. Hanauer. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5(2):119–133.PubMed
21.
go back to reference Borrelli, O., C. Bascietto, F. Viola, M. Bueno de Mesquita, M. Barbato, V. Mancini, et al. 2004. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig. Liver. Dis. 36(5):342–347. MayPubMedCrossRef Borrelli, O., C. Bascietto, F. Viola, M. Bueno de Mesquita, M. Barbato, V. Mancini, et al. 2004. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig. Liver. Dis. 36(5):342–347. MayPubMedCrossRef
22.
go back to reference Playford, R. J., T. Marchbank, R. A. Goodlad, R. A. Chinery, R. Poulsom, and A. M. Hanby. 1996. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc. Natl. Acad. Sci. USA. 93:2137–2142. doi:10.1073/pnas.93.5.2137.PubMedCrossRef Playford, R. J., T. Marchbank, R. A. Goodlad, R. A. Chinery, R. Poulsom, and A. M. Hanby. 1996. Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc. Natl. Acad. Sci. USA. 93:2137–2142. doi:10.​1073/​pnas.​93.​5.​2137.PubMedCrossRef
23.
go back to reference Marchbank, T., H. M. Cox, R. A. Goodlad, A. S. Giraud, S. F. Moss, R. Poulsom, et al. 2001. Effect of ectopic expression of rat trefoil factor family 3 (rTFF3, intestinal trefoil factor) in the jeunum of transgenic mice. J. Biol. Chem. 26:24008–24096. Marchbank, T., H. M. Cox, R. A. Goodlad, A. S. Giraud, S. F. Moss, R. Poulsom, et al. 2001. Effect of ectopic expression of rat trefoil factor family 3 (rTFF3, intestinal trefoil factor) in the jeunum of transgenic mice. J. Biol. Chem. 26:24008–24096.
25.
go back to reference Cook, G. A., M. Familari, L. Thim, and A. S. Giraud. 1999. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett. 456(1):155–159. Jul 30PubMedCrossRef Cook, G. A., M. Familari, L. Thim, and A. S. Giraud. 1999. The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett. 456(1):155–159. Jul 30PubMedCrossRef
26.
go back to reference Podolsky, D. K. 2000. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J. Gastroenterol. 35(suppl 12):69–74. doi:10.1007/PL00009980.PubMed Podolsky, D. K. 2000. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J. Gastroenterol. 35(suppl 12):69–74. doi:10.​1007/​PL00009980.PubMed
28.
go back to reference Stallmach, A., T. Marth, B. Weiss, B. M. Wittig, A. Hombach, C. Schmidt, et al. 2004. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Cohn’s disease and experimental colitis in vivo. Gut 53(3):339–345. MarPubMedCrossRef Stallmach, A., T. Marth, B. Weiss, B. M. Wittig, A. Hombach, C. Schmidt, et al. 2004. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Cohn’s disease and experimental colitis in vivo. Gut 53(3):339–345. MarPubMedCrossRef
29.
go back to reference Wallace, J. L., and C. M. Keenan. 1990. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am. J. Physiol. 258:527–534. Wallace, J. L., and C. M. Keenan. 1990. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am. J. Physiol. 258:527–534.
30.
go back to reference Fedorak, R. N., L. R. Empey, C. MacArthur, and L. D. Jewell. 1990. Micoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 98:615–625.PubMed Fedorak, R. N., L. R. Empey, C. MacArthur, and L. D. Jewell. 1990. Micoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 98:615–625.PubMed
32.
go back to reference Soriano-Izquierdo, A., M. Gironella, A. Massaguer, F. E. May, A. Salas, M. Sans, et al. 2004. Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. J. Leukoc. Biol. 75(2):214–223. FebPubMedCrossRef Soriano-Izquierdo, A., M. Gironella, A. Massaguer, F. E. May, A. Salas, M. Sans, et al. 2004. Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. J. Leukoc. Biol. 75(2):214–223. FebPubMedCrossRef
33.
go back to reference Tran, C. P., G. A. Cook, N. D. Yeomans, L. Thim, and A. S. Giraud. 1999. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44:636–642.PubMedCrossRef Tran, C. P., G. A. Cook, N. D. Yeomans, L. Thim, and A. S. Giraud. 1999. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44:636–642.PubMedCrossRef
34.
go back to reference Podolsky, D. K., K. Lynch-Devaney, J. L. Stow, P. Oates, B. Murgue, M. DeBeaumont, et al. 1993. Identification of human intestinal trefoil factor: goblet cell-specific expression of a peptide targeted for apical secretion. J. Biol. Chem. 268:6694–6702.PubMed Podolsky, D. K., K. Lynch-Devaney, J. L. Stow, P. Oates, B. Murgue, M. DeBeaumont, et al. 1993. Identification of human intestinal trefoil factor: goblet cell-specific expression of a peptide targeted for apical secretion. J. Biol. Chem. 268:6694–6702.PubMed
35.
go back to reference Suemori, S., K. Lynch-Devaney, and D. K. Podolsky. 1991. Identification and characterization of rat intestinal trefoil factor: Tissue- and cell-specific member of the trefoil protein family. Proc. Natl. Acad. Sci. USA. 88:11017–11021. doi:10.1073/pnas.88.24.11017.PubMedCrossRef Suemori, S., K. Lynch-Devaney, and D. K. Podolsky. 1991. Identification and characterization of rat intestinal trefoil factor: Tissue- and cell-specific member of the trefoil protein family. Proc. Natl. Acad. Sci. USA. 88:11017–11021. doi:10.​1073/​pnas.​88.​24.​11017.PubMedCrossRef
37.
go back to reference Baus-Loncar, M., M. Lubka, C. M. Pusch, W. R. Otto, R. Poulsom, and N. Blin. 2007. Cytokine regulation of the trefoil factor family binding protein GKN2 (GDDR/TFIZ1/blottin) in human gastrointestinal epithelial cells. Cell. Physiol. Biochem. 20(1–4):193–204.PubMed Baus-Loncar, M., M. Lubka, C. M. Pusch, W. R. Otto, R. Poulsom, and N. Blin. 2007. Cytokine regulation of the trefoil factor family binding protein GKN2 (GDDR/TFIZ1/blottin) in human gastrointestinal epithelial cells. Cell. Physiol. Biochem. 20(1–4):193–204.PubMed
38.
go back to reference Baus-Loncar, M., J. Schmid, el.-N. Lalani, I. Rosewell, R. A. Goodlad, G. W. Stamp, et al. 2005. Trefoil factor 2 (TFF2) deficiency in murine digestive tract influences the immune system. CellPhysiol. Biochem. 16(1–3):31–42. doi:10.1159/000087729. Baus-Loncar, M., J. Schmid, el.-N. Lalani, I. Rosewell, R. A. Goodlad, G. W. Stamp, et al. 2005. Trefoil factor 2 (TFF2) deficiency in murine digestive tract influences the immune system. CellPhysiol. Biochem. 16(1–3):31–42. doi:10.​1159/​000087729.
39.
go back to reference Kurt-Jones, E. A., L. Cao, F. Sandor, A. B. Rogers, M. T. Whary, P. R. Nambiar, et al. 2007. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect. Immun. 75(1):471–480. JanPubMedCrossRef Kurt-Jones, E. A., L. Cao, F. Sandor, A. B. Rogers, M. T. Whary, P. R. Nambiar, et al. 2007. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect. Immun. 75(1):471–480. JanPubMedCrossRef
40.
go back to reference Ya-Qin, Z., and T. Xiao-Di. 2005. TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am. J. Physiol. Cell Physiol. 289:1085–10093. doi:10.1152/ajpcell.00185.2005.CrossRef Ya-Qin, Z., and T. Xiao-Di. 2005. TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am. J. Physiol. Cell Physiol. 289:1085–10093. doi:10.​1152/​ajpcell.​00185.​2005.CrossRef
42.
go back to reference Schwarz, N. T., B. Engel, M. K. Eskandari, J. C. Kalff, J. R. Grandis, and A. J. Bauer. 2002. Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology 123:586–598. doi:10.1053/gast.2002.34777.PubMedCrossRef Schwarz, N. T., B. Engel, M. K. Eskandari, J. C. Kalff, J. R. Grandis, and A. J. Bauer. 2002. Lipopolysaccharide preconditioning and cross-tolerance: the induction of protective mechanisms for rat intestinal ileus. Gastroenterology 123:586–598. doi:10.​1053/​gast.​2002.​34777.PubMedCrossRef
43.
go back to reference Wolf, D., J. Schumann, K. Koerber, A. K. Kiemer, A. M. Vollmar, G. Sass, et al. 2001. Low molecular- weight hyaluronic acid induces nuclear factor-κB-dependent resistance against tumor necrosis factor-α-mediated liver injury in mice. Hepatology 34:535–547. doi:10.1053/jhep.2001.27218.PubMedCrossRef Wolf, D., J. Schumann, K. Koerber, A. K. Kiemer, A. M. Vollmar, G. Sass, et al. 2001. Low molecular- weight hyaluronic acid induces nuclear factor-κB-dependent resistance against tumor necrosis factor-α-mediated liver injury in mice. Hepatology 34:535–547. doi:10.​1053/​jhep.​2001.​27218.PubMedCrossRef
46.
48.
go back to reference Kobayashi, M., M. N. Kweon, H. Kuwata, R. D. Schreiber, H. Kiyono, K. Takeda, et al. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. Clin. Invest. 111(9):1297–1308. May 1 Kobayashi, M., M. N. Kweon, H. Kuwata, R. D. Schreiber, H. Kiyono, K. Takeda, et al. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. Clin. Invest. 111(9):1297–1308. May 1
Metadata
Title
Effects of Trefoil Peptide 3 on Expression of TNF-α, TLR4, and NF-κB in Trinitrobenzene Sulphonic Acid Induced Colitis Mice
Authors
Xu Teng
Ling-Fen Xu
Ping Zhou
Hong-Wei Sun
Mei Sun
Publication date
01-04-2009
Publisher
Springer US
Published in
Inflammation / Issue 2/2009
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-009-9110-x

Other articles of this Issue 2/2009

Inflammation 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.